Upjohn Inc, founded in 1886 and headquartered in Kalamazoo, Michigan, is a global pharmaceutical company focused on delivering innovative therapies for patients in need. Originally part of the Upjohn Company before its merger with Pfizer, Upjohn specializes in producing generic medicines and established branded pharmaceuticals, serving a diverse range of therapeutic areas.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| UPJOHN 1.65% 2025-06-22 USDUpjohn Inc | United States | 2025-06-22 | 1.650 | 4.70 |
| UPJOHN 1.65% 2025-06-22 USDUpjohn Inc | United States | 2025-06-22 | 1.650 | 4.70 |
| UPJOHN 2.30% 2027-06-22 USDUpjohn Inc | United States | 2027-06-22 | 2.300 | 4.26 |
| UPJOHN 2.30% 2027-06-22 USDUpjohn Inc | United States | 2027-06-22 | 2.300 | 4.26 |
| UPJOHN 3.85% 2040-06-22 USDUpjohn Inc | United States | 2040-06-22 | 3.850 | 6.16 |
| UPJOHN 3.85% 2040-06-22 USDUpjohn Inc | United States | 2040-06-22 | 3.850 | 6.16 |
| UPJOHN 4.00% 2050-06-22 USDUpjohn Inc | United States | 2050-06-22 | 4.000 | 7.21 |
| UPJOHN 4.00% 2050-06-22 USDUpjohn Inc | United States | 2050-06-22 | 4.000 | 7.21 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Upjohn Inc began issuing bonds in the early 1990s, with notable bond offerings aimed at financing research and development activities. In 2020, the company issued $2 billion in 10-year notes to bolster its capital structure, reflecting a current yield of 3.5%, competitive within the industry. The bonds feature a sinking fund provision that allows gradual repayment, positioning Upjohn favorably during changing market conditions. The most recent issuance received strong demand, underscoring investor confidence in Upjohn’s strategic direction and product pipeline.